Advagene Biopharma Co., Ltd. (TPEX:6709)

Taiwan flag Taiwan · Delayed Price · Currency is TWD
25.55
-0.30 (-1.16%)
Apr 20, 2026, 1:15 PM CST
Market Cap1.51B +17.0%
Revenue (ttm)n/a
Net Income-68.29M
EPS-1.15
Shares Out59.38M
PE Ration/a
Forward PEn/a
Dividendn/a
Ex-Dividend Daten/a
Volume102,600
Average Volume72,208
Open25.70
Previous Close25.85
Day's Range25.50 - 25.80
52-Week Range15.75 - 41.00
Beta0.85
RSI24.62
Earnings DateMay 14, 2026

About Advagene Biopharma

Advagene Biopharma Co., Ltd. engages in the research and development of vaccine technology and related products in Taiwan. It engages in the development of nasal spray influenza vaccine; respiratory allergy treatment vaccine, including rhinitis and asthma; COVID-19 immunotherapy; and other vaccines. The company was founded in 2006 and is based in Taipei, Taiwan. [Read more]

Industry Biotechnology
Sector Healthcare
Founded 2006
Employees 16
Stock Exchange Taipei Exchange
Ticker Symbol 6709
Full Company Profile

Financial Performance

Financial Statements